United Kingdom· GB-APID-40391411000001109
Aspaveli 1080mg/20ml solution for infusion vials
A pegcetacoplan product containing pegcetacoplan, registered in United Kingdom by Swedish Orphan Biovitrum Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Pegcetacoplan is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AJ03 (pegcetacoplan), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Pegcetacoplan · ATC L04AJ03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Pegcetacoplan
- Manufacturer
- Swedish Orphan Biovitrum Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AJ03
- ATC class
- Pegcetacoplan
- Defined daily dose
- 0.3 g, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 4
- gtin07350031443363
- gtin07350031443295
- gtin07350031443370
- gtin07350031443301
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pegcetacoplan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEmpaveliApellis Pharmaceuticals, Inc.
- CzechiaASPAVELISwedish Orphan Biovitrum AB (publ), Stockholm
- SwitzerlandAspaveli
- FinlandASPAVELISwedish Orphan Biovitrum AB (publ)
- FranceASPAVELI 1080 mg, solution pour perfusionSWEDISH ORPHAN BIOVITRUM (SUEDE)
- BelgiumAspaveli 1080 mgSwedish Orphan Biovitrum (Publ)
- IcelandASPAVELI*Swedish Orphan Biovitrum AB (publ)
- NetherlandsAspaveli 1080 mg oplossing voor infusieApellis Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aspaveli
- Liechtenstein · Aspaveli
- Norway · Aspaveli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5cd90504-5584-4be0-a422-c6110c7ef319 GET /v1/drugs/5cd90504-5584-4be0-a422-c6110c7ef319?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40391411000001109",
"desc": "Aspaveli 1080mg/20ml solution for infusion vials (Swedish Orphan Biovitrum Ltd)",
"form": "Solution for infusion",
"vpid": "40558611000001109",
"source": "dmd",
"vtm_id": "1162432003",
"strength": "54 mg",
"substance": "Pegcetacoplan",
"ingredient": "Pegcetacoplan",
"supplier_code": "4232111000001108"
}See everything about pegcetacoplan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.